



İsim Burak Yulug

Doğum yeri ve yılı 18.10.1973, İzmir

Medeni Durum Evli

Derece	Bölüm / Program	Üniversite	Yıl
Lisans ve Y. Lisans	TIP FAKULTESİ	TIP FAKULTESİ	1991–1998
Tıpta Uzmanlık	NÖROLOJİ	DOKUZ EYLUL UNIVERSITESİ TIP FAKULTESİ	1999–2003 Aralık
Doçentlik	Nöroloji	ÜAK	19.06.2012

Eğitim 1980-1991 Almanya-Münih ve Türkiye-İzmir'de İlk-Orta ve Lise eğitimi

Lisans 1991-1998 Tıp fakültesi eğitimi (Almanya ve Türkiye-Atatürk Üniv)

Mesleki deneyim 1998-1999 Medizinischen Hochschule Hannover Tıp fakültesinde Almanca-Türkçe, İngilizce-Almanca, İngilizce-Türkçe simultan tercümanlık ve Almanya'da Tıp doktorluğunun tanınması

1999-2003 **Tıp fakültesi Uzmanlık Eğitimi (Dokuz Eylül Üniversitesi Nöroloji Anabilim Dalı)**

2002-2003 **Göttingen Üniversitesi Nöroloji ve Max Planck**

araştırma enstitüsü moleküler nörobiyoloji biriminde adult santral sinir sisteminde programlanmış hücre ölümü üzerine araştırma faaliyetleri. Özellikle fokal serebral iskemi ve aksotomi modelinde sinyal transduksiyonu ve apoptoz mekanizmaları.

25.12.2003 -01.06.2004

Dokuz Eylül Üniversitesi Nöroloji Anabilim Dalı uzman doktor olarak faaliyet

2005-2006

Zürich Üniversitesi Tıp fakültesi, deneysel Nöroloji Bilim Dalı (Prof.Dr Kilic) ve **Münster Üniversitesi (Almanya)** Nöroloji Anabilim Dalında **Prof. Dr. Schabitz-Stroke** Ünitesi araştırmacı ve asistan doktor olarak faaliyet (özellikle deneysel stroke modellerinde apoptoz mekanizmaları ve aksotomi modelinde retinal ganglion hücre ölüm mekanizmaları)

2006-2008

Zürich üniversitesi Nöroloji (Prof Dr Kilic), Bern üniversitesi Psikiyatri anabilim dallarında periyodik araştırma faaliyetleri. **Bern Üniversitesi-İsviçre psikiyatri anabilim dalında klinik psikiyatri asistanlığı yanısıra fMRI eğitimi (Prof Dr W.K Strik)**

2008-2012

Beyin araştırmaları laboratuvarı (Prof. Dr. Ertugrul Kilic) (Epizodik araştırma faaliyetleri deneysel felç modeli-nöroproteksiyon)

2009-Eylül

Cambridge Üniversitesi Nöroloji ABD Stroke araştırma birimine ‘‘Clinical Research Associate’’ kadrosuna kabul (**Prof J.C Baron**).

2009-Aralık

Cambridge Üniversitesi Nöroloji ABD ‘‘Preclinical Research Associate’’ kadrosuna kabul (**Prof J.C Baron, Prof Compston**).
Stroke fonksiyonel görüntüleme birimi

2009-2011

Regensburg Üniversitesi Almanya Nöroloji kliniği Felç Ünitesi Prof Dr Ertugrul Kilic

yönetiminde deneysel nöroloji çalışmaları
-Deneysel nöroloji alanında doçentlik başvurusunun
kabulü. (**Prof Ulrich Bogdahn**).

2011-2014	Prof Dr Ertugrul Kilic yönetiminde deneysel nöroloji çalışmaları
2012-	Nöroloji Doçentliği
2014-	Medipol Üniversitesi Nöroloji ABD Stroke ve Deneysel Nöroloji bölüm sorumlusu Sinir rejenerasyonu laboratuvarı (REMER) grup lideri (Aktif olarak yürütülen Moleküler Nörolojiye ilişkin Tübitak 1001 projelerinde yürütücülük ve arařtırmacılık: Proje No: 115S471 ve 117S124)

Yabancı Diller

Almanca (çok iyi), İngilizce (çok iyi)

Resmi Hakemi olunan yurt dışı dergiler

Brain Research
Brain Research Bulletin
CNS Drugs
Neural Regeneration Research
Biological Psychiatry
Neuropsychiatric Disease and Treatment
CNS Spectrums
Journal of Psychiatry Research
International Journal of Biomedical Science

Editorial Board üyeliğinde bulunulan yurt dışı dergiler

Neural Regeneration Research
Journal of Neuroquantology
BMC Neurology
Journal of Experimental Stroke and Translational Medicine
Data set papers Neurology and Neuroscience

A.1 ULUSLARARASI YAZILMIŞ KİTAP BÖLÜMLERİ

1- Cam E, Kilic E, **Yulug B**, Ritz M: Occlusion of the Middle Cerebral Artery in Rats.
Poindron P, Piguët P (eds): New Animal Models of Human Neurological Diseases. BioValley Monogr. Basel,
Karger, 2008, vol 2, pp 52-65

2-**Yulug B**, Schäbitz WR. Neuroprotective Therapy for Stroke and Ischemic Disease. Combination therapy with
thrombolysis. Book Chapter (Springer/Prof. Lapchak and Prof. John Zhang)

A.2.ULUSLARARASI HAKEMLİ DERGİLERDE (SCI) YAYIMLANAN MAKALELER

A.1 ULUSLARARASI YAZILMIŞ KİTAP BÖLÜMLERİ

1- Cam E, Kilic E, **Yulug B**, Ritz M: Occlusion of the Middle Cerebral Artery in Rats.
Poindron P, Piguët P (eds): New Animal Models of Human Neurological Diseases. BioValley Monogr. Basel,
Karger, 2008, vol 2, pp 52-65

2-**Yulug B**, Schäbitz WR. Neuroprotective Therapy for Stroke and Ischemic Disease. Combination therapy with
thrombolysis. Book Chapter (Springer/Prof. Lapchak and Prof. John Zhang)

A.2.ULUSLARARASI HAKEMLİ DERGİLERDE (SCI) YAYIMLANAN MAKALELER

1: **Yulug B** Hanoglu L Kilic U, Kilic E, Schabitz WR. The therapeutic role of Rifampicin in Alzheimer's
Disease (Psychiatry and Clinical Neurosciences in press 2018)

2: **Yulug B**, Hanoglu L, Ksanmemmedov E, Arıcı Düz O, Polat B, Hanoglu T, Gunal MY, Kilic E. Beyond The
Therapeutic Effect Of Rtns In Alzheimer's Disease: A Possible Neuroprotective Role Of Hippocampal Bdnf? :
A Minireview. Minireview in Medicinal Chemistry. 2017-Sep 27.

3: **Yulug B**, Hanoglu L, Kilic E. Does sleep disturbance affect the amyloid clearance mechanisms in Alzheimer's
disease? Psychiatry Clin Neurosci. 2017 May 18.

4: **Yulug B**, Hanoglu L, Kilic E. The neuroprotective effect of focused ultrasound: New perspectives on an old
tool. Brain Res Bull. 2017 May;131:199-206.

5: **Yulug B**, Hanoglu L, Kilic E. Toward a Personalized Medicine in Wake-Up Stroke? CNS Neurol Disord
Drug Targets. 2017 Jul 27.

- 6: **Yulug B**, Elmir Ksanmemmedov, Hacı Murat A, Hanoglu L, A Proposed etiology for isolated small right temporal infarct and circumflex coronary artery stenosis or What Was First: The Egg or the Chicken? International Journal Of Current Medical And Pharmaceutical Research, Vol. 3, Issue, 03, pp.1451-53, March, 2017
- 7: **Yulug B**, Tavlı AM, Cakir T, Hanoglu L. Depressive Disorder After Pontine Ischemic Stroke: Clinicoradiologic Correlates. J Neuropsychiatry Clin Neurosci. 2016 Winter;28(1):e1-2.
- 8: **Yulug B**, Hanoglu L, Cakır T, Polat B, Tavlı AM, Yılmaz NH. Pure Posterior Alien Hand Syndrome Following a Cerebrovascular Lesion: Clinicoradiological Correlates. J Clin Neurol. 2016 Apr;12(2):243-4.
- 9: **Yulug B**, Hanoglu L, Tavlı AM, Cakir T, Khanmammadov E, Olmuscelik O. 18F-FDG-PET Correlates of Impulse Control Disorder in a Diabetic Patient. Endocr Metab Immune Disord Drug Targets. 2016;16(3):224-227.
- 10: **Yulug B**, Hanoglu L, Yamaner FY, Kilic E, Schabitz WR. Commentary : Hypothesis Focused Ultrasound and NXY-059 in Experimental Cerebral Ischemia: A New Therapeutic Opportunity? CNS Neurol Disord Drug Targets. 2016;15(9):1010-1013.
- 11: **Yulug B**, Hanoglu L. Pramipexole Responsive Neck Numbness: The Therapeutic Role of Dopamine Agonists in the Spinal Cord Indicating to a Common Spinal Pathophysiology with Restless Leg Syndrome (RLS)? Curr Clin Pharmacol. 2016;11(3):221-222.
- 12: **Yulug B**, Hanoglu L, Kilic E, Polat B, Schabitz WR. The Neuroprotective Role of Repetitive Transcranial Magnetic Stimulation (rTMS) for Neurodegenerative Diseases: A Short Review on Experimental Studies. Mini Rev Med Chem. 2016;16(16):1269-1273.
- 13: **Yulug B**, Hanoglu L, Tavli AM, Cakir T, Olmuscelik O, Pakoz B, Ünlü G. Topiramate: A Novel Therapeutic Candidate for Diabetes and Aggression? Positron Emission Tomography (PET) Findings. Cent Nerv Syst Agents Med Chem. 2016;16(3):227-230.
- 14: **Yulug B**, Hanoglu L, Tavli AM, Yılmaz NH, Kılıc E. The Brain Protective Effect of rTMS (Repetitive Transcranial Magnetic Stimulation) in Depression: A Mini-Review in Animal Studies. Med Chem. 2016;12(6):500-5.
- 15: **Yulug B**, Hanoglu L, Schabitz WR. Headache and spontaneous glabellar ecchymosis: more than a self-injury behavior? Psychiatry Clin Neurosci. 2015 Feb;69(2):124.
- 16: **Yulug B**, Hanoglu L, Kilic E. The neuroprotective role of vesicular monoamine transporter 2 in neurodegenerative diseases. Med Chem. 2015;11(2):104-8.

- 17: **Yulug B**, Hanoglu L, Kilic E, Schabitz WR. RIFAMPICIN: an antibiotic with brain protective function. *Brain Res Bull.* 2014 Aug;107:37-42.
- 18: **Yulug B**, Schabitz WR. Towards a multimodal treatment of depression: a minireview on the potential role of antibiotics. *Mini Rev Med Chem.* 2011 Oct;11(11):984-7.
- 19: **Yulug B**, Erkol G, Kilic E. An interesting link between microgravity and psychiatric diseases. *J Neuropsychiatry Clin Neurosci.* 2010 Fall;22(4):451-g.e12-451.e12.
- 20: **Yulug B**, Ozan E, Kilic E. Brain-derived neurotrophic factor polymorphism as a genetic risk for depression? A short review of the literature. *J Neuropsychiatry Clin Neurosci.* 2010 Winter;22(1):123.E5-6.
- 21: **Yuluğ B**, Kilic E. Olanzapine does not aggravate ischemic neuronal injury by focal cerebral ischemia: a dose related restriction of the neuroprotective effect? *Med Chem.* 2009 May;5(3):279-82.
- 22: **Yuluğ B**, Ozan E, Gönül AS, Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. *Brain Res Bull.* 2009 Mar 30;78(6):267-9.
- 23: **Yulug B**. Neuroprotective treatment strategies for poststroke mood disorders: A minireview on atypical neuroleptic drugs and selective serotonin re-uptake inhibitors. *Brain Res Bull.* 2009 Sep 28;80(3):95-9.
- 24: **Yulug B**, Ozan E. Buprenorphine: a safe agent for opioid dependent patients who are under the increased risk of stroke? *J Opioid Manag.* 2009 May-Jun;5(3):134.
- 25: **Yulug B**, Ozan E, Aydin N, Kirpınar I. Brain-derived neurotrophic factor polymorphism: more than a prognostic factor during depression? *J Neuropsychiatry Clin Neurosci.* 2009 Fall;21(4):471-2.
- 26: **Yulug B**, Bakar M, Ozan E. Brain damage after preischemic locomotor activity. *J Neuropsychiatry Clin Neurosci.* 2008 Winter;20(1):123-4.
- 27: **Yulug B**, Bakar M, Ozan E. The neuroprotective effect of olanzapine. *J Neuropsychiatry Clin Neurosci.* 2008 Winter;20(1):107-8.
- 28: **Yulug B**, Bakar M, Ozer H H, Yilmaz M, Unlü B. Paroxysmal kinesigenic dyskinesia and cervical disc prolapse with cord compression: more than a coincidence? *J Neuropsychiatry Clin Neurosci.* 2008 Spring;20(2):237-9.
- 29: **Yulug B**, Bakar M, Karapolat I, Güzel O, Schabitz WR. A case of idiopathic basal ganglia calcification presenting with only acting-out attacks and mild cognitive impairment: PET findings. *J Neuropsychiatry Clin Neurosci.* 2007 Summer;19(3):348-9.
- 30: **Yulug B**, Bakar M, Karapolat I, Güzel O, Schabitz WR. Topiramate improves glucose metabolism in choreatic and depressive patient: PET findings. *J Neuropsychiatry Clin Neurosci.* 2007 Summer;19(3):346-7.

- 31: **Yulug B**, Cam E, Yildiz A, Kilic E. Buprenorphine does not aggravate ischemic neuronal injury in experimental focal cerebral ischemia. *J Neuropsychiatry Clin Neurosci*. 2007 Summer;19(3):331-4.
- 32: **Yulug B**, Yildiz A, Güzel O, Kilic E, Schäbitz WR, Kilic E. Risperidone attenuates brain damage after focal cerebral ischemia in vivo. *Brain Res Bull*. 2006 May 31;69(6):656-9.
- 33: **Yulug B**, Yildiz A, Hüdaoglu O, Kilic E, Cam E, Schäbitz WR. Olanzapine attenuates brain damage after focal cerebral ischemia in vivo. *Brain Res Bull*. 2006 Dec 11;71(1-3):296-300.
- 34: Hanoglu L, **Yulug B**, Cakir T, Sogukkanli K, Duz OA, Atasever T. The Therapeutic Role of Lamotrigine And Topiramate In A Depressive Patient With Anxiety Symptoms And Cognitive Decline: Neurometabolic Correlates. *Curr Clin Pharmacol*. 2016 Sep 4.
- 35: Hanoglu L, Yildiz S, Polat B, Demirci S, Tavli AM, Yilmaz N, **Yulug B**. Therapeutic Effects of Rivastigmine and Alfa-Lipoic Acid Combination in the Charles Bonnet Syndrome: Electroencephalography Correlates. *Curr Clin Pharmacol*. 2016;11(4):270-273.
- 36: Kartal Ö, Aydınöz S, Kartal AT, Kelestemur T, Caglayan AB, Beker MC, Karademir F, Süleymanoğlu S, Kul M, **Yulug B**, Kilic E. Time dependent impact of perinatal hypoxia on growth hormone, insulin-like growth factor 1 and insulin-like growth factor binding protein-3. *Metab Brain Dis*. 2016 Aug;31(4):827-35.
- 37: Kelestemur T, **Yulug B**, Caglayan AB, Beker MC, Kilic U, Caglayan B, Yalcin E, Gundogdu RZ, Kilic E. Targeting different pathophysiological events after traumatic brain injury in mice: Role of melatonin and memantine. *Neurosci Lett*. 2016 Jan 26;612:92-7.
- 38: Kilic U, Caglayan AB, Beker MC, Gunal MY, Caglayan B, Yalcin E, Kelestemur T, Gundogdu RZ, **Yulug B**, Yilmaz B, Kerman BE, Kilic E. Particular phosphorylation of PI3K/Akt on Thr308 via PDK-1 and PTEN mediates melatonin's neuroprotective activity after focal cerebral ischemia in mice. *Redox Biol*. 2017 Aug;12:657-665.
- 39: Beker MC, Caglayan AB, Kelestemur T, Caglayan B, Yalcin E, **Yulug B**, Kilic U, Hermann DM, Kilic E. Effects of normobaric oxygen and melatonin on reperfusion injury: role of cerebral microcirculation. *Oncotarget*. 2015 Oct 13;6(31):30604-14.
- 40: Cakaloz B, Akay AP, Bober E, **Yulug B**. Thyroid function and oppositional defiant disorder: more than a coincidence in prepubertal boys with attention-deficit hyperactivity disorder? *J Neuropsychiatry Clin Neurosci*. 2011 Spring;23(2):E9-E10.

- 41: Parlayan E, **Yulug B**, Bakar M, Gumustas O. Neurometabolic correlations of donepezil and rivastigmine in dementia patients: a different neuroprotective effect. *J Neuropsychiatry Clin Neurosci*. 2009 Summer;21(3):348-50.
- 42: Cam E, **Yulug B**, Ozan E. MK 801: a possible neuroprotective agent by poststroke depression? *J Neuropsychiatry Clin Neurosci*. 2008 Summer;20(3):367-8.
- 43: Cam E, **Yulug B**, Cengiz N, Poelkin E, Isýk D, Bakar M, Ozan E, Kilic E. Melatonin: a suitable agent for depression associated with stroke? *J Neuropsychiatry Clin Neurosci*. 2008 Fall;20(4):498-500.
- 44: Ozakbas S, Idiman E, **Yulug B**, Pakoz B, Bahar H, Gulay Z. Development of multiple sclerosis after vaccination against hepatitis B: a study based on human leucocyte antigen haplotypes. *Tissue Antigens*. 2006 Sep;68(3):235-8.
- 45: **Yulug B**, Kilic U, Kilic E, Bähr M. Rifampicin attenuates brain damage in focal ischemia. *Brain Res*. 2004 Jan 16;996(1):76-80.
- 46: Kilic E, Kilic U, **Yulug B**, Hermann DM, Reiter RJ. Melatonin reduces disseminate neuronal death after mild focal ischemia in mice via inhibition of caspase-3 and is suitable as an add-on treatment to tissue-plasminogen activator. *J Pineal Res*. 2004 Apr;36(3):171-6.
- 47: Kilic E, Weishaupt JH, Kilic U, Rohde G, **Yulug B**, Peters K, Hermann DM, Bähr M. The superoxide dismutase1 (SOD1) G93A mutation does not promote neuronal injury after focal brain ischemia and optic nerve transection in mice. *Neuroscience*. 2004;128(2):359-64.
- 48: Kilic U, Kilic E, Lingor P, **Yulug B**, Bähr M. Rifampicin inhibits neurodegeneration in the optic nerve transection model in vivo and after 1-methyl-4-phenylpyridinium intoxication in vitro. *Acta Neuropathol*. 2004 Jul;108(1):65-8. Epub 2004 May 8. PubMed PMID: 15138778.
- 49: Ozakbas S, Idiman E, Baklan B, **Yulug B**. Childhood and juvenile onset multiple sclerosis: clinical and paraclinical features. *Brain Dev*. 2003 Jun;25(4):233-6.

A.3 ULUSAL DERGİLERDE YAYINLANMIŞ YAYIMLANAN MAKALELER

- 1: Yılmaz NH, Şeker M, Omaygenç MO, Yaka U, Eryiğit N, **Yuluğ B**. Ortostatik Hipotansiyon ile Birlikte İzlenen Lhermitte-Duclos Hastalığı Olgusu *Türk J Neurol* 2016;22:130-132
- 2: Çakmur R, Ozakbas S, **Yulug B**. Pür Akinezi: Bir olgu sunumu Parkinson Hastalığı ve Hareket bozuklukları dergisi 2000: 3; 49-52

3: Dönmez B, Cakmur R, **Yulug B.** Nöromyotoni: Olgu sunumu Parkinson Hastalığı ve Hareket bozuklukları dergisi 2001; 4: 96-99

4: Bakar M, **Yulug B.** Mild Cognitive Impairment. Turkish J Neurol-Special Topics 2009 2(1): 88-93